Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Oditrasertib in Healthy East Asian Adults
NCT04982991Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oditrasertib in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Quantifiable Concentration and 1 more. Started Aug 2021; status: completed.
02
Drugs
oditrasertib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04982991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982991.